Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Harvard Business School
Daiichi Sankyo
UBS
Citi
Deloitte

Generated: July 16, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,871,779

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,871,779 protect, and when does it expire?

Patent 8,871,779 protects OPANA ER and is included in one NDA.

This patent has eleven patent family members in nine countries.

Summary for Patent: 8,871,779
Title:Process for preparing morphinan-6-one products with low levels of .alpha.,.beta.-unsaturated ketone compounds
Abstract: The present invention generally relates to processes for preparing highly pure morphinan-6-one products. The processes involve reducing the concentration of .alpha.,.beta.-unsaturated ketone compounds present as impurities in morphinan 6 one products or reaction mixtures including morphinan 6 one compounds by treatment with a sulfur-containing compound. (A) ##STR00001##
Inventor(s): Buehler; Henry J. (St. Louis, MO), Dummitt; William E. (St. Louis, MO), Mannino; Anthony (Maryland Heights, MO), Aubuchon; Dennis C. (Arnold, MO), Gu; Hong (Oak Park, CA)
Assignee: Mallinckrodt LLC (Hazelwood, MO)
Application Number:11/915,606
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,871,779
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 8,871,779
Patent Claim Types:
see list of patent claims
Compound; Formulation;

Drugs Protected by US Patent 8,871,779

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-001 Dec 9, 2011 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-002 Dec 9, 2011 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-003 Dec 9, 2011 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-004 Dec 9, 2011 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-005 Dec 9, 2011 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-006 Dec 9, 2011 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-007 Dec 9, 2011 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,871,779

PCT Information
PCT FiledMarch 02, 2007PCT Application Number:PCT/US2007/005256
PCT Publication Date:September 13, 2007PCT Publication Number: WO2007/103105

International Family Members for US Patent 8,871,779

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 448231 ➤ Try a Free Trial
Australia 2007224221 ➤ Try a Free Trial
Canada 2644095 ➤ Try a Free Trial
China 101395159 ➤ Try a Free Trial
Germany 602007003197 ➤ Try a Free Trial
European Patent Office 1994034 ➤ Try a Free Trial
Japan 2009528366 ➤ Try a Free Trial
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Mallinckrodt
Accenture
Moodys
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.